[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-diseases":649},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,157,0,25,[9,47,73,104,130,159,188,212,238,255,280,312,339,358,387,407,433,457,477,497,528,546,567,593,613],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100360929",false,"NCT03979534","Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach","ProReRePro","Inclusion Criteria:\n\n* All adult patients followed on the unit for advanced CKD, with Kidney disease stage 4-5 or stage 3 with fast progression and without contraindications.\n\nExclusion Criteria:\n\n* Malnutrition or short life-expectancy\n* Patients aged less than 18 years old\n* Pregnant women,\n* Incapacity to complete the free-consent form,\n* Pateints refusing participation in the study,\n* Patients without healthcare coverage.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Nephrology care continues to progress and recommendations are now focused on delaying as much as possible the need for renal replacement therapy (\"intent-to-defer\"strategy). Protein restriction is a valuable tool for stabilizing chronic kidney disease (CKD) and retarding the need for renal replacement therapy, but the best diet to be prescribed is still matter of discussion. This study is aimed at identifying implementation strategies for nutritional management of advanced CKD.",[26],"Chronic Kidney Diseases",[28,29,30,31,32,33],"low-protein diet","pre-dialysis","chronic kidney disease","nutritional care","start of dialysis","incremental dialysis","RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":38},"2019-04-01",{"date":42,"type":20},"2028-04-01",{"name":44,"class":45},"Centre Hospitalier le Mans","OTHER",2,{"id":48,"slug":4,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100601857","NCT07115953","Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension","Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)","SWYFT","Inclusion Criteria:\n\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)\n4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery anatomy\n2. Individual has undergone prior renal denervation\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73m2\n6. Individual has one or more episode(s) of orthostatic hypotension\n7. Individual is pregnant, nursing or planning to become pregnant\n8. Individual has documented primary pulmonary hypertension\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%",{"count":55,"type":20},130,[23],"The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.",[59,60,61,26,62],"Hypertension","Vascular Diseases","Cardiovascular Diseases","Diabetes Mellitus","2026-06-29",{"date":35,"type":38},{"date":66,"type":38},"2025-09-22",{"date":68,"type":20},"2029-12-31",{"name":70,"class":71},"Medtronic Vascular","INDUSTRY",21,{"id":74,"slug":4,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100585805","NCT06907147","SPYRAL GEMINI Pilot Study","Global Pilot Study of rEnal and Hepatic coMbINed denervatIon in Subjects With Uncontrolled Hypertension With and Without High Cardiovascular Risk","SPYRAL GEMINI","Inclusion Criteria:\n\nAll Subjects (both cohorts):\n\n1. ≥18 and ≤80 years of age.\n2. Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \\\u003C180 mmHg and an office DBP ≥ 90 mmHg.\n3. 24-hour average SBP ≥140 mmHg and \\\u003C170 mmHg measured by ABPM at Baseline.\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery OR common hepatic artery anatomy.\n2. Prior renal or hepatic denervation.\n3. History of NYHA Class III or IV heart failure within 6 months of screening visit.\n4. Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability.\n5. Documented Type 1 diabetes or use of insulin within 6 months.\n6. Secondary cause of hypertension.\n7. Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement.\n8. Estimated glomerular filtration rate (eGFR) of \\\u003C40\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Primary pulmonary arterial hypertension.\n11. History or evidence of active \u002F suspected chronic liver or biliary disease.\n12. Current or chronic pancreatitis.","80 Years",{"count":82,"type":20},175,[23],"The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.",[59,60,61,26,62],[87,88,89,90,91,59,61,60,92,93,94],"Renal Insufficiency","Chronic Disease","Disease Attributes","Pathologic Processes","Kidney Diseases","Denervation","Renal Denervation","Hepatic Denervation","2026-06-22",{"date":97,"type":38},"2026-06-24",{"date":99,"type":38},"2025-05-01",{"date":101,"type":20},"2029-12-22",{"name":70,"class":71},18,{"id":105,"slug":4,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100552521","NCT06474169","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients.","LYMPHOVIR-IRCT","Inclusion Criteria:\n\n1. Male or female ≥ 18 years\n2. Informed participants who did not object to participating in the study\n\nExclusion Criteria:\n\n1. Chronic progressive infections\n2. Prior organ transplantation (including bone marrow transplantation)\n3. Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion\n4. Participant under guardianship, curatorship or deprived of liberty\n5. Pregnant or breastfeeding women",true,{"count":19,"type":20},"OBSERVATIONAL","This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease.\n\nThe study population was patients with chronic kidney disease.",[26],[117,118,119,120],"end-stage kidney disease","T-cells response","Immunodeficiency","Proof of concept of T-cell therapy",{"date":122,"type":38},"2026-06-25",{"date":124,"type":38},"2024-11-27",{"date":126,"type":20},"2026-12",{"name":128,"class":45},"Centre Hospitalier Régional d'Orléans",1,{"id":131,"slug":4,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100643970","NCT07667517","Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease","Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","Inclusion Criteria:\n\n* 1\\. Age \\>= 18 years at the time of signing informed consent, male or female.\n* 2\\. Type 2 diabetes mellitus.\n* 3\\. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2, and UACR 30-2000 mg\u002Fg (mean of 3 measurements).\n* 4\\. Serum potassium \\\u003C= 5.0 mmol\u002FL.\n* 5\\. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.\n* 6\\. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.\n\nExclusion Criteria:\n\n* 1\\. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.\n* 2\\. HbA1c \\>= 8.0%.\n* 3\\. On renal replacement therapy.\n* 4\\. Acute kidney injury within 180 days before the screening visit.\n* 5\\. Hepatic impairment (Child-Pugh class C).\n* 6\\. Blood pressure \\> 160\u002F100 mmHg, or systolic blood pressure \\\u003C 90 mmHg, at the screening visit.\n* 7\\. Bilateral renal artery stenosis.\n* 8\\. Known hypersensitivity to the study drug (active substance or excipients).\n* 9\\. Treatment with finerenone within 60 days before screening.\n* 10\\. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.\n* 11\\. NYHA class II-IV heart failure.\n* 12\\. Addison's disease.\n* 13\\. Gastrointestinal surgery that may affect drug absorption.\n* 14\\. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy \\\u003C 12 months).\n* 15\\. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.\n* 16\\. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.\n* 17\\. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).\n* 18\\. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.\n* 19\\. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.\n* 20\\. History of alcohol or drug abuse.\n* 21\\. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.\n* 22\\. Any other condition deemed by the investigator to make the participant unsuitable for the study.",{"count":137,"type":20},148,[139],"PHASE4","This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 and UACR 30-2000 mg\u002Fg) who are already receiving a maximum tolerated dose of an ACE inhibitor or ARB. A total of 148 participants are randomized 1:1, stratified by baseline UACR (\\\u003C300 vs \\>=300 mg\u002Fg), to oral finerenone (10 or 20 mg once daily, titrated by serum potassium and eGFR) or matching placebo, on top of standard background therapy, for 180 days, followed by a 30-day off-treatment follow-up. Albuminuria regression is defined as both an improvement in Kidney Disease: Improving Global Outcomes albuminuria category, from A3 to A2 or A1, or from A2 to A1, and a more than 30% reduction in urinary albumin-to-creatinine ratio from baseline. The outcome will be reported as the percentage of participants meeting this definition at Day 180.",[142,143,26],"Albuminuria","Type 2 Diabetes Mellitus (T2DM)",[145,146,147,148,149],"Finerenone","Nonsteroidal mineralocorticoid receptor antagonist","Urine albumin-to-creatinine ratio","KDIGO","Albuminuria regression","NOT_YET_RECRUITING","2026-06-19",{"date":122,"type":38},{"date":37,"type":20},{"date":155,"type":20},"2027-12-31",{"name":157,"class":45},"First Affiliated Hospital of Zhejiang University",13,{"id":160,"slug":4,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":129},"100506940","NCT05880914","Precision Medicine Approaches to Renal Osteodystrophy","PMaROD","Inclusion Criteria:\n\n1. Study participant has provided informed consent\n2. Age ≥ 18 years\n3. CKD Stages 3-5D regardless of kidney transplantation status\n4. CKD5D patients receiving maintenance hemodialysis for at least 3 months\n5. Clinically indicated treatment for renal hyperparathyroidism, renal osteodystrophy and\u002For Osteoporosis\n6. PTH, BSAP and CTX meets defined thresholds for low or high turnover ROD type or a Bone biopsy evidence of low or high turnover based\n\nExclusion Criteria:\n\n1. Currently receiving treatment in an investigational device or drug study, or less than 30 days since ending treatment on an investigational device or drug study(s)\n2. Currently receiving investigational procedures\u002Fdrugs from another study while participating in this study\n3. Use of etelcalcetide, bisphosphonate, denosumab, teriparatide, abaloparatide or romosozumab during the 6 months prior to study enrollment; however, participant can be included if being treated with bone active agent but will have class change to an agent that will result in a change in bone turnover from low to high or high to low\n4. New use of cinacalcet over the prior 6 months\n5. Use of Zoledronic Acid (Reclast) less than 24 months from study enrollment for patients with eGFR \\\u003C30mL\u002Fminute\n6. Anticipated or scheduled kidney transplant during the study period or less than 1 year from receiving a kidney transplant\n7. For patients with a solid organ transplant, less than 1 year from receiving the transplant\n8. Patient has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator\n9. Metabolic bone diseases not related to the kidney (e.g., Paget's, Osteogenesis Imperfecta)\n10. Endocrinopathy (e.g., untreated hyperthyroidism)\n11. Malignancy within the last 5 years (except non-melanoma skin cancers or cervical carcinoma in situ)\n12. Patient is pregnant or nursing\n13. Weight \\>300 pounds (scanner limitation)\n14. Allergy to tetracycline or demeclocycline\n15. Patients on non-aspirin anticoagulants that cannot be reasonably held for biopsy\n16. Patient unable to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures to the best of the patient and Investigator's knowledge",{"count":166,"type":20},40,"Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease patients and parathyroid hormone and bone alkaline phosphatase have insufficient accuracy for turnover type to safely and confidently guide treatment of renal osteodystrophy. In the present investigation, the investigators will study a microRNA approach as a novel non-invasive biomarker of turnover for renal osteodystrophy.",[169,26,170,171,172],"Renal Osteodystrophy","CKD-MBD","Bone Turnover Rate Disorder","Secondary Hyperparathyroidism",[174,175,176,177,178],"Bone biopsy","microRNA","HR-pQCT","Bone biomarkers","Bone imaging","2026-06-11",{"date":181,"type":38},"2026-06-12",{"date":183,"type":38},"2022-12-21",{"date":185,"type":20},"2027-06-30",{"name":187,"class":45},"Thomas Nickolas",{"id":189,"slug":4,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":17,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100561686","NCT06593392","Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus","KOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe Pruritus","Inclusion Criteria:\n\n* 1\\. Participant must be ≥12 to \\\u003C18 years of age at the time of informed consent.\n* 2\\. Participants with CKD on HD 3 times weekly for at least 12 weeks prior to the informed consent procedure who can continue HD without changing its frequency or method.\n* 3\\. Participants whose WI-NRS score in the 7-day run-in period (meets both of the below:\n* a) WI-NRS scores have been recorded for at least 4 days through a 7-day run-in period.\n* b) The mean value of the recorded WI-NRS scores is \\>4.0\n* 4\\. Over the last 3 months prior to screening, the participant has had at least 1 of the following:\n* a) At least 2 single-pool Kt\u002FV measurements ≥1.2 on different dialysis days\n* b) At least 2 urea reduction ratio measurements ≥65% on different dialysis days\n* c) 1 single-pool Kt\u002FV measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis day\n* 5\\. Prescription dry body weight ≥20 kg\n* 6\\. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* 7\\. Participant and\u002For legal guardian (as required) is capable of providing the appropriate signed informed consent and where appropriate, assent.\n\nExclusion Criteria:\n\n* 1\\. Known to be non-compliant with HD treatments and deemed unlikely by the Investigator to complete the study\n* 2\\. Planned to receive a kidney transplant during the study. Note: being listed on a kidney transplant list is not an exclusion criterion.\n* 3\\. Participants with itching caused by conditions other than chronic renal failure or complications of chronic renal failure, which could in the opinion of the Investigator affect the efficacy evaluation (e.g., atopic dermatitis, chronic urticaria).\n* 4\\. Participants with localised itch restricted to the palms of the hands.\n* 5\\. Participants with pruritus only during the dialysis session (by participant report).\n* 6\\. Participants with known concurrent hepatic cirrhosis or severe hepatic impairment (e.g., Child-Pugh Class C).\n* 7\\. Significant systolic or diastolic heart failure (e.g., New York Heart Association Class IV congestive heart failure).\n* 8\\. Participants with concurrent malignancy except excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ that has been excised or resected completely.\n* 9\\. Severe mental illness or cognitive impairment (e.g., dementia) or other concurrent mental disorder that, in the opinion of the Investigator, would compromise the validity of study measurements.\n* 10\\. Conditions associated with clinically important disruptions to the blood brain barrier (for example, primary brain malignancies, CNS metastases or other inflammatory conditions, active multiple sclerosis, advanced Alzheimer's disease) that in the Investigator's opinion may be associated with unacceptable risk for CNS effects.\n* 11\\. Acute or unstable medical condition(s) that in the Investigator's opinion, may be associated with increased risk to the participant, or may interfere with study assessments, outcomes, or the ability to provide written informed consent or comply with study procedures.\n* 12\\. Participant is receiving ongoing ultraviolet B treatment and anticipates receiving such treatment during the study.\n* 13\\. New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening.\n* 14\\. New or change of prescription for opioids, gabapentin, or pregabalin within 14 days prior to screening.\n* 15\\. Participant is receiving prohibited medication (e.g., nalfurafine hydrochloride, opioid antagonists) that cannot be stopped at least 14 days before enrolment in the study.\n* 16\\. Participant has known hypersensitivity to the study intervention or any components of the difelikefalin formulation.\n* 17\\. Known or suspected history of alcohol, narcotic, or other drug abuse or substance dependence within 12 months prior to screening or participant with any alcoholic beverage intake of more than two units per day more than once per week.\n* 18\\. Participation in any other investigational device or drug study \\\u003C30 days prior to screening, or current treatment with other investigational agent(s).\n* 19\\. Serum ALT, AST greater than 3× the reference ULN.","12 Years",{"count":103,"type":20},[197],"PHASE2","Rationale:\n\n* People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy.\n* Difelikefalin is a medicine that can treat the itching related to long term kidney disease.\n* Clinical studies have shown difelikefalin to reduce itching in adults on haemodialysis, while being safe and tolerable.\n* The current study is being done in adolescents aged 12 to 17 years on haemodialysis who have moderate to severe itching related to long term kidney disease to assess if difelikefalin is safe in this age group.\n\nThe aims of the study are:\n\nMain aim: To assess the safety of difelikefalin in adolescents who are on haemodialysis and have itching related to long term kidney disease\n\nSecondary aim: To measure the amount of difelikefalin that enters the blood in adolescents who are on haemodialysis and have itching related to long term kidney disease\n\nStudy Design At least 18 adolescents, aged 12 to 17 years, who are on haemodialysis and have itching related to long term kidney disease will take part in this study.\n\nAll study participants will receive difelikefalin 3 (or up to 4) times weekly for up to 12 weeks. The study duration for a participant is up to 17 to 18 weeks; during this period, participants will visit the clinic 3 times weekly (during their haemodialysis visits).",[200,26],"Pruritus",[202],"Chronic kidney disease associated pruritus","2026-06-10",{"date":179,"type":38},{"date":206,"type":20},"2026-06-17",{"date":208,"type":20},"2029-08-15",{"name":210,"class":71},"Vifor Fresenius Medical Care Renal Pharma",16,{"id":213,"slug":4,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":129},"100571091","NCT06715735","Theory-based Health Behaviour Change Intervention in Individuals of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of A Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension), and CKD;\n* Participants are capable of understanding and providing informed consent, their cognitive function will be screened by the abbreviated mental test with a score higher than seven;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese.\n\nExclusion Criteria:\n\n* Participants who have medical contraindications to exercise, including walking;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":219,"type":20},160,[23],"This study will adopt a 2-arm, pretest-posttest, and assessor-blind RCT design to examine the effectiveness of a theory-based health behaviour change intervention on WC (primary outcome), kidney function (eGFR, primary outcome), dietary behaviour, PA, exercise capacity, and self-efficacy of dietary behaviour and PA among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nA total of 160 adults with metabolic syndrome and chronic kidney disease will be recruited, with 80 participants in each group. Data will be collected at 3-time points (baseline, immediate post-intervention and 1-month post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[26,223],"Metabolic Syndrome",[223,225,226,227,228,229],"Chronic Kidney Disease","Waist Circumference","Kidney Function","Behaviour Change Intervention","Health Action Process Approach","2026-06-09",{"date":179,"type":38},{"date":233,"type":38},"2024-12-20",{"date":235,"type":20},"2026-10-30",{"name":237,"class":45},"Chinese University of Hong Kong",{"id":239,"slug":4,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":21,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":129},"100556643","NCT06527768","Theory-based Health Behaviour Change Intervention in Patients of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of a Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension) and CKD;\n* No medical contraindications to exercise, including walking;\n* Participants are capable of understanding and providing informed consent;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese;\n* Stay in Chengdu during the study period.\n\nExclusion Criteria:\n\n* Participants who cannot perform brisk walking exercise;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Participants who have a cognitive impairment, which will be screened by the abbreviated mental test with a score lower than seven;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":166,"type":20},[23],"The pilot study will adopt a 2-arm, pretest-posttest, and assessor-blind randomized controlled trial design to examine the feasibility and acceptability of a theory-based health behaviour change intervention and examine its effects on waist circumference (primary outcome), kidney function (estimated glomerular filtration rate, urine albumin-to-creatinine ratio, primary outcome), dietary behaviour, physical activity, exercise capacity and self-efficacy of diet behaviour and physical activity among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nResearchers will compare the theory-based health behaviour change intervention to usual care to see if the theory-based health behaviour change intervention can reduce waist circumference and preserve kidney function over three months.\n\nA total of 40 adults with metabolic syndrome and chronic kidney disease will be recruited, with 20 participants in each group. Data will be collected at two-time points (baseline and immediate post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[26,223],[223,225,226,227,228],{"date":179,"type":38},{"date":251,"type":38},"2024-07-31",{"date":253,"type":20},"2026-07-31",{"name":237,"class":45},{"id":256,"slug":4,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":261,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":129},"100600239","NCT07094906","Handgrip Exercise Training and CKD","Neural and Vascular Modulation With Isometric Handgrip Training in Chronic Kidney Disease","Inclusion Criteria:\n\n* Patients with CKD (Stages IIIa and IV),\n* Ages 45-85 years who do not regularly exercise (defined as exercising less than 20 minutes twice per week), willing and able to cooperate with the protocol.\n* CKD Stages III and IV will be defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc\u002Fminute as calculated by the modified CKD-EPI equations.\n* Patients with CKD must have stable renal function (no greater than a 20% reduction in eGFR over the prior 3 months).\n\nExclusion Criteria:\n\n* Severe CKD (eGFR\\\u003C15 cc\u002Fminute)\n* Metabolic alkalosis (serum bicarbonate \\> 28 meq\u002FL)\n* Ongoing drug or alcohol abuse\n* Diabetic neuropathy\n* Any serious systemic disease that might influence survival\n* Severe anemia with hgb level \\\u003C10 g\u002FdL\n* Clinical evidence of congestive heart failure or ejection fraction below 35%, symptomatic heart disease determined by prior electrocardiogram, stress test, and\u002For history, treatment with central alpha agonists (clonidine)\n* Uncontrolled hypertension with BP greater than 170\u002F100 mm Hg\n* Low blood pressure with BP less than 100\u002F50\n* Pregnancy or plans to become pregnant\n* Current treatment with MAO inhibitors\n* Inability to perform handgrip exercise","45 Years","85 Years",{"count":264,"type":20},50,[23],"The purpose of this study is to find out if regular handgrip exercise performed at home can improve blood pressure at rest and during exercise in patients with chronic kidney disease (CKD).\n\nThis study is also intended to understand what causes an increase in blood pressure at rest and during exercise (i.e., increased adrenaline levels, or decreased ability of blood vessels to dilate). Patients with CKD will be recruited from primary care, Nephrology and other subspecialty Clinics throughout the Emory Healthcare System. Participants will attend 4 visits of 2-3 hours and 3 visits of 1-2 hours. The home exercise training will last for 8 weeks.",[26],[269,270,271],"Handgrip","Isometric handgrip exercise training (IHT)","Blood pressure variability","2026-06-08",{"date":203,"type":38},{"date":275,"type":20},"2026-09",{"date":277,"type":20},"2027-12",{"name":279,"class":45},"Emory University",{"id":281,"slug":4,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":21,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":129},"100638389","NCT07622134","Effectiveness of Health Literacy Program for Polypharmacy Patients (HLP-CKD)","Effectiveness of the Health Literacy Promotion Program to Prevent Chronic Kidney Disease of Patients Who Use Polypharmacy","HLP-CKD","Inclusion Criteria:\n\n* Patients aged 55-74 years diagnosed with non-communicable diseases.\n* Currently taking 5 or more medications daily (Polypharmacy) for at least 6 months.\n* Have at least one risk factor for chronic kidney disease (e.g., Hypertension or Diabetes).\n* Able to communicate, read, and write in Thai.\n* Willing to participate in the 8-week program and follow-up assessments.\n\nExclusion Criteria:\n\n* Patients already diagnosed with Chronic Kidney Disease (CKD) stage 3 - 5.\n* Having severe cognitive impairment or psychiatric disorders that prevent participation.\n* Having severe complications or being in an unstable clinical condition.\n* Planning to move out of the study area during the 12-week study period.","55 Years","74 Years",{"count":290,"type":20},104,[23],"This study aims to evaluate the effectiveness of a health literacy promotion program in preventing chronic kidney disease (CKD) among patients who use multiple medications (polypharmacy). Participants will be divided into two groups: an experimental group receiving the health literacy program and a control group receiving standard care. The study will measure improvements in health literacy levels and CKD prevention behaviors over a specific period. It is expected that the program will help patients better manage their medications and reduce the risk of developing kidney complications.",[26,294,295],"Polypharmacy","Health Literacy",[297,298,299,300,301,302],"Health Literacy Program","CKD Prevention","Medication Management","Nursing Intervention","Randomized Controlled Trial","Thailand","2026-06-03",{"date":305,"type":38},"2026-06-04",{"date":307,"type":20},"2026-06-15",{"date":309,"type":20},"2026-11-15",{"name":311,"class":45},"Nakhon Pathom Rajabhat University",{"id":313,"slug":4,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":319,"targetDuration":321,"studyType":113,"phases":4,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":129},"100637453","NCT07626710","Impact of Trans-catheter Aortic Valve Implantation on Renal Function","Impact of Trans-catheter Aortic Valve Implantation on Kidney Response to Contrast Dye Administration: an Observational Registry","TAVIKOD","Inclusion Criteria:\n\n* Age \\>18 years with a life expectancy \\>1 year;\n* Patient candidate for percutaneous aortic valve implantation after formal indication of our \"Heart Team\".\n* Patient performed at least one contrast-based exam other than the TAVI procedure in the previous two months.\n* Patients had adequate renal function assessment after each contrast medium administration (TAVI procedure included) with at least three post-procedural measurements in the following 5 days.\n* Patients were informed of the possibility to be the object of anonymized data collection for study protocols approved by the internal Ethical Committee and had provided written informed consent to the procedure (for patients before 2018) or had provided written informed consent to the research purposes of IRCCS (for patients from 2018 to date).\n\nExclusion Criteria:\n\n* Female with childbearing potential or lactating;\n* Acute or chronic end-stage renal dysfunction defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2);\n* Candidate for dialysis treatment;\n* Co-morbidities that could interfere with the completion of study procedures, or life expectancy of less than 1 year;\n* Absent or incomplete renal function assessment after each contrast-based procedure;\n* Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;",{"count":320,"type":20},1000,"5 Years","Both contrast-induced acute kidney injury (AKI) and pre-existing chronic kidney disease are associated with an increased mortality risk in patients requiring aortic valve replacement. Nonetheless, the direct haemodynamic impact of the aortic barrage (i.e. pre-renal mechanism) on renal function compromising and its reversibility in patients undergoing trans-catheter aortic valve implantation (TAVI) is unknown.\n\nThis registry aims to evaluate the effect of severe aortic stenosis removal on the risk of contrast-induced acute renal injury (CI-AKI) during TAVI procedures and on renal function evolution",[324,26,325],"Aortic Valve Stenosis","Renal Failure Acute Chronic",[327,328,329,330],"Trans-catheter aortic valve implantation","Contrast-induced acute renal injury","Kidney failure","Observational registry","2026-05-31",{"date":305,"type":38},{"date":334,"type":38},"2024-08-30",{"date":336,"type":20},"2033-08-30",{"name":338,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":340,"slug":4,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":129},"100626076","NCT07430930","Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease","PROMPT-CKD","Inclusion Criteria:\n\n1. Male or female, aged ≥18 years\n2. Diagnosed with CKD defined by an eGFR ≤60 mL\u002Fmin\u002F1.732 on two occasions at least ≥3 months apart with most recent being ≤60 or eGFR 60-90 mL\u002Fmin\u002F1.73m2 with an uACR ≥30 mg\u002Fg or eGFR \\>90 mL\u002Fmin\u002F1.73m2 with an uACR ≥30 mg\u002Fg.\n3. Eligible to receive at least 1 of the following CKD GDMT: ACEi\u002FARB, SGLT2i, MRA or GLP-1 RA based on the following criteria.\n4. To receive an ACEi\u002FARB: eGFR ≥15 ml\u002Fmin\u002F1.732 and have diagnosis of hypertension based on ICD10 code or proteinuria (uACR ≥30 mg\u002Fg).\n5. To receive an SGLT2i: have heart failure (defined by ICD10 code); or T2D; or uACR ≥200 mg\u002Fg; or eGFR ≥20 ml\u002Fmin\u002F1.732.\n6. To receive an MRA: ns-MRA: have an eGFR ≥25 ml\u002Fmin\u002F1.732, diagnosis of T2D, normal serum potassium (≤4.8 mmol\u002FL) and albuminuria (\\>30 mg\u002Fg). s-MRA: have an eGFR ≥45 ml\u002Fmin\u002F1.732 and heart failure, hyperaldosteronism, or refractory hypertension.\n7. To receive a GLP-1 RA: have T2D.\n8. Ability to take oral medication.\n\nExclusion Criteria:\n\n1. Allergy to the GDMT for which the patient is eligible\n2. End-stage kidney disease\n3. CKD stage 5 (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2)\n4. Glomerulonephritis (by ICD-10 code)\n5. Polycystic kidney disease (by ICD-10 code)\n6. History of kidney transplant\n7. End-stage heart failure\n8. Eligible to receive ACEi\u002FARB but having blood pressure \\\u003C110\u002F70 mmHg or have known renal artery stenosis\n9. Eligible to receive SGLT2i but pregnant or breastfeeding, type 1 DM, history of euglycemic diabetic ketoacidosis or Fournier's gangrene based on ICD10 code.\n10. Eligible to receive MRA but serum potassium ≥5 mmol\u002FL, have office SBP \\\u003C100 mmHg, adrenal insufficiency based on ICD10 code or concomitant treatment with CYP3A4 inhibitors (Strong: grapefruit, grapefruit juice, itraconazole. Moderate: erythromycin. Weak: amiodarone).\n11. Eligible to receive GLP-1 RA but pregnant; or found to have personal history of pancreatitis; or personal or family history of medullary thyroid cancer or MEN type 2 based on ICD10 code or gastroparesis based on ICD10 code.\n12. Opted out of EHR-based research.",{"count":320,"type":20},[23],"This study is a cluster-randomized clinical trial to evaluate whether a tailored, user-centered, clinical decision support (CDS) tool can positively influence prescriber behavior and increase prescription of guideline-directed medical therapy (GDMT) among patients with Chronic Kidney Disease (CKD) across a single healthcare center.",[26],"2026-05-21",{"date":351,"type":38},"2026-05-26",{"date":353,"type":20},"2026-06",{"date":355,"type":20},"2028-06",{"name":357,"class":45},"Yale University",{"id":359,"slug":4,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":21,"phases":366,"briefSummary":368,"conditions":369,"keywords":373,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":386},"100542051","NCT06337838","Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial","BRACKETS","Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:\n\n1. One of either:\n\n   1.1. eGFR \\\u003C25 ml\u002Fmin\u002F1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;\n2. Planned noncardiac surgery (elective, urgent, or emergency surgery);\n3. Expected to require at least an overnight hospital admission after surgery;\n4. Age ≥18 years; and\n5. Informed consent is obtained to participate in the BRACKETS-Pilot Trial.\n\nExclusion Criteria:\n\n1. Undergoing cardiac surgery;\n2. Undergoing intracranial neurosurgery;\n3. Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access;\n4. Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid;\n5. Hypersensitivity or known allergy to TXA;\n6. History of seizure disorder;\n7. Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft;\n8. History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome;\n9. Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of childbearing potential and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective contraception; or\n10. Previously enrolled in the BRACKETS-Pilot Trial.\n\nEligibility criteria specific to the desmopressin factorial component of trial\n\nInclusion criteria:\n\n1\\. Included in the TXA factorial.\n\nExclusion criteria:\n\n1. The hospital does not have access to desmopressin;\n2. Planned use of prophylactic desmopressin;\n3. Most recent serum sodium concentration \\\u003C 130 mEq\u002FL;\n4. Known or suspected von Willebrand disease (any kind), hemophilia, or platelet function disorder; or\n5. Hypersensitivity or known allergy to desmopressin.",{"count":19,"type":20},[367],"PHASE3","The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.",[26,370,371,372],"Acute Kidney Injury","Bleeding","Surgery",[374,375,376],"Major Noncardiac Surgery","Tranexamic Acid","Desmopressin","2026-05-20",{"date":379,"type":38},"2026-05-22",{"date":381,"type":38},"2025-06-09",{"date":383,"type":20},"2027-06",{"name":385,"class":45},"Hamilton Health Sciences Corporation",3,{"id":388,"slug":4,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":16,"minAge":393,"maxAge":80,"enrollmentInfo":394,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":386},"100376770","NCT04185844","American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)","AI-CRIC","Inclusion Criteria:\n\n* Glomerular Filtration Rate (GFR): eGFR of =\\>61\\\u003C80 and microalbuminuria \\> 30 or eGRF of =\\\u003C60 (no microalbuminuria required).\n\nExclusion Criteria:\n\n1. Unable or unwilling to provide informed consent\n2. life expectancy \\\u003C3 years;\n3. institutionalized subjects;\n4. End stage renal disease or renal transplant;\n5. renal cancer;\n6. myeloma;\n7. immunosuppression;\n8. Polycystic kidney disease;\n9. participation in any clinical trial,\n10. current pregnancy\n11. current incarceration.\n12. Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.","21 Years",{"count":395,"type":20},500,"Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - \"CRIC 2018\" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.",[62,26,398,61],"Heart Diseases","2026-05-18",{"date":377,"type":38},{"date":402,"type":38},"2020-08-31",{"date":404,"type":20},"2028-06-30",{"name":406,"class":45},"University of New Mexico",{"id":408,"slug":4,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":21,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":129},"100546407","NCT06394531","Effects of Jaboticaba (Plinia Cauliflora) Supplementation in Chronic Kidney Disease Patients","Jaboticaba (Plinia Cauliflora) as a Strategy to Modulate Inflammation, Oxidative Stress, and Gut Dysbiosis in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Aged 18 to 75 years\n* Clinical diagnosis of Chronic Kidney Disease\n* Conservative treatment group: CKD stages 3 and 5 receiving nutritional treatment for at least 6 months\n* Hemodialysis group: Hemodialysis patients for more than 6 months\n\nExclusion Criteria:\n\n* Patients pregnant\n* Smokers\n* Using antibiotics in the last 3 months\n* Autoimmune diseases\n* Clinical diagnosis of infectious diseases\n* Clinical diagnosis of Cancer\n* Clinical diagnosis of AIDS","75 Years",{"count":415,"type":20},30,[23],"The increase prevalence of chronic kidney disease (CKD) over the years represent a significant public health problem. The role of inflammation and oxidative stress in the pathophysiology of CKD, as well as progression and comorbidities, is already well consolidated. The gut microbiota composition imbalance may also be a risk factor contributing to the increased conditions mentioned above, and to uremic toxins release and endotoxemia. The literature has indicated the use of bioactive compounds as a nonpharmacological treatment strategies for the management of non-communicable diseases (NCDs), such as CKD and its complications. In this context, jaboticaba (Plinia Cauliflora) emerges as a potential therapeutic approach as it is a source of phenolic compounds, such as anthocyanins, flavonols, ellagitannins, and phenolic acids. Such phenolic compounds may have beneficial effects in patients with CKD, such as anti-inflammatory, antioxidant, modulation of the intestinal microbiota, hypotensive and hypoglycemic effects. These combined effects can help manage risk factors and CKD itself, and associated complications. Therefore, this research project aims to add scientific knowledge, providing a non-pharmacological therapeutic approach to be implemented in clinical practice and in the care of patients with CKD, with the aim of modulating inflammation, oxidative stress, microbiota composition, and improving the quality of life of these patients. Therefore, this study aims to evaluate the effects of jaboticaba (Plinia Cauliflora) supplementation on complications associated with CKD.",[26],[420,421,422,423,424],"chronic kidney diseases","jaboticaba","inflammation","oxidative stress","microbitoa","2026-05-14",{"date":427,"type":38},"2026-05-15",{"date":37,"type":20},{"date":430,"type":20},"2028-07-01",{"name":432,"class":45},"Universidade Federal Fluminense",{"id":434,"slug":4,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":413,"enrollmentInfo":439,"targetDuration":4,"studyType":21,"phases":441,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":46},"100538236","NCT06288204","Green Propolis Extract and Royal Jelly in Hypertensive Patients and\u002For With Chronic Kidney Disease","Association of Green Propolis Extract and Royal Jelly to Modulate Inflammation and Oxidative Stress in Hypertensive Patients and\u002For With Chronic Kidney Disease","Inclusion Criteria:\n\n* patients in stages 3 and 5 of CKD (GFR from 15 to 59 mL\u002Fmin),\n* patients receiving ambulatorial nutrition treatment at least 6 months\n* patients on regular Hemodialysis treatment for at least 6 months\n* patients using one to three antihypertensive drugs\n\nExclusion Criteria:\n\n* autoimmune and infectious diseases,\n* diabetes\n* cancer\n* AIDS\n* pregnant women\n* patients using catabolic drugs or antibiotics;\n* patients with catheter access to hemodialysis;\n* patients using antioxidant vitamin supplements, prebiotics, probiotics, symbiotic,\n* Patients on regular intake of propolis who are allergic to corn starch or report being allergic to bee stings.\n* patients with acute myocardial infarction (AMI) and\u002For cerebrovascular accident (CVA)",{"count":440,"type":20},153,[23],"This work aims to evaluate the effects of the association of green propolis extract with royal jelly on inflammation and oxidative stress in participants with chronic kidney diseases (CKD) and Systemic arterial hypertension (SAH), in a longitudinal, randomized, double-blind, placebo-controlled clinical trial that will be carried out for 2 months.",[26,59,61],[30,445,446,422,423,447,448,449,450],"hypertension","cardiovascular disease","green propolis","royal jelly","Nrf2","Nuclear factor kappa-B",{"date":427,"type":38},{"date":453,"type":38},"2024-10-01",{"date":455,"type":20},"2027-07-31",{"name":432,"class":45},{"id":458,"slug":4,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":21,"phases":465,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":129},"100538124","NCT06286748","Beetroot Extract Supplementation Associated With an Exercise Protocol for Chronic Kidney Disease Patients","Effects of Beetroot Extract Supplementation Associated With an Exercise Protocol on Oxidative Stress, Inflammation, and Functional Capacity in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Patients with CKD undergoing conservative treatment (stages G3a-G4);\n* Aged between 18 and 65 years old;\n* Patients undergoing nutritional monitoring for more than 6 months.\n\nExclusion Criteria:\n\n* Patients using catabolic drugs;\n* Smokers\n* Pregnant women;\n* Using antibiotics and of proton pump inhibitors in the last 3 months;\n* Antioxidant supplements and habitual intake of beetroot or nitrate supplement;\n* Those who are clinically unstable (unstable angina, atrial fibrillation, significant cardiac arrhythmia and acute illness in the last month; and glycemic lability);\n* Unable to exercise (amputation without prosthesis); musculoskeletal pain at rest or with minimal physical activity, inability to sit or walk without assistance, use of a walking device, dyspnea at rest or with light exertion;\n* Those with autoimmune diseases and infectious diseases, cancer, liver disease and AIDS.\n* Patients with parathormone (PTH) levels above 500pg\u002FmL;\n* Those who are allergic or intolerant to the components of the juice.\n* Patients with any impediment to completing the proposed exercise protocol, such as due to travel or difficulty accessing the location where the research will be carried out.","65 Years",{"count":7,"type":20},[23],"Chronic kidney disease (CKD) patients often present systemic inflammation and oxidative stress, resulting in metabolic disorders and high rates of disease-associated cardiovascular death. The literature has indicated that dietary control, the use of bioactive compounds, and the practice of regular physical exercise are essential for the prevention and management of CKD and its complications. In this context, beetroot (Beta vulgaris rubra) deserves attention as it is a source of several bioactive compounds, such as nitrate, betaine, and betalain, with beneficial effects for CKD patients, including anti-inflammatory, antioxidant effects, reduction of blood pressure, and vasodilatory action. The antioxidant and anti-inflammatory properties, in addition to their vasodilatory and antihypertensive capacity, can make supplementation of beetroot an excellent nutritional strategy to help in the treatment of CKD patients. So, this research project will bring contributions to the scientific world, providing strategies for application in clinical practice and the care of patients with CKD, on the use of beetroot associated with an exercise protocol as a non-pharmacological strategy in modulating inflammation, oxidative stress, and improved functional capacity. Furthermore, when supplemented hours before physical training, has been identified as an important factor in improving performance in these activities. Therefore, this study aims to evaluate the effects of supplementation (acute and chronic) of beetroot extract associated with an exercise protocol on complications associated with CKD.",[26],[30,469,470,422,423],"beetroot","exercise",{"date":427,"type":38},{"date":473,"type":38},"2024-04-10",{"date":475,"type":20},"2026-12-10",{"name":432,"class":45},{"id":478,"slug":4,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":483,"targetDuration":4,"studyType":21,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":129},"100638111","NCT07585526","Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD\u002FNAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.","Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD\u002FNAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease. A Randomized Control Trial.","Inclusion Criteria:\n\n1. Age \\> 18 years \\\u003C80years\n2. Patient of MASLD\u002F NAFLD cirrhosis with clinical ascites\n3. Stable eGFR-(\\>60 ml\u002Fmin\u002F1.73m2) calculated using MDRD-6 equation: eGFR (ml\u002Fmin\u002F1.73 m2) = 170 × (Scr)-0.999 × (Age)-0.176 × (0.762 if patient is female) × (1.180 if black) × (SUN)-0.170 × (Albumin)0.318\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years \\>80 years\n2. K\u002FC\u002FO systemic hypertension.\n3. Coagulopathy- INR \\>2.5\n4. Post TIPS\n5. CTP class C\n6. Any intrinsic\u002Fstructural kidney disease.\n7. Refractory Ascites\n8. Patient with HCC(outside MILAN criteria) or portal vein thrombosis\n9. Pregnancy or Lactating mother\n10. Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment\n11. Patients with anuria, acute renal failure, or Addison's disease\n12. Heart failure (NYHA II to IV)\n13. History of hospitalization for hyperkalaemia or acute renal failure induced by previous aldosterone antagonist treatment\n14. Ongoing drug or alcohol abuse\n15. Uncontrolled type 2 DM ( HbA1C \\> 9)\n16. MI, unstable angina, stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment\n17. Coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass grafting \\[CABG\\]) or valvular repair\u002Freplacement within 12 weeks prior to enrolment or is planned to undergo any of these procedures after randomisation\n18. Diagnosed Mixed ascites (additional etiology of ascites apart from portal hypertension)\n19. Patients who are on spirinolactone with stable ascites in the past 12 weeks\n20. Refusal to give consent",{"count":219,"type":20},[23],"Renal dysfunction is a frequent and clinically important complication in cirrhosis, and MASLD\u002FNAFLD is associated with increased risk of incident CKD; however, finerenone has not been specifically studied in MASLD-cirrhosis populations despite proven cardiorenal benefits in diabetic CKD. This monocentric, open-label, randomized controlled trial at the Department of Hepatology, ILBS, New Delhi will enroll 160 adults (18-80 years) with MASLD\u002FNAFLD cirrhosis, clinical grade I-II ascites, and stable eGFR ≥60 mL\u002Fmin\u002F1.73 m² (MDRD-6), with key exclusions including CTP class C, refractory ascites, significant coagulopathy, intrinsic kidney disease, recent major cardiovascular events, and other protocol-defined contraindications. Participants will receive standard medical treatment (dietary measures, diuretics as indicated, metabolic control, complication management, albumin\u002Fbeta-blockers as needed) and will be randomized to finerenone (5 mg\u002Fday uptitrated to 10-20 mg\u002Fday) versus spironolactone (50 mg\u002Fday uptitrated to 100-200 mg\u002Fday). The primary endpoint is incident CKD at 6 months , defined as sustained eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m² over 3 months. Secondary endpoints include MAKE\u002FMACE\u002FMALO at 6 months, drug-related adverse events (including hyperkalemia, hyponatremia, hypotension, hyperuricemia), AKI\u002FAKD episodes, renal biomarkers (e.g., cystatin C, UPCR), ascites response, liver severity scores (MELD 3.0\u002FMELD-Na\u002FCTP), and metabolic\u002Finflammatory\u002Fendothelial markers (e.g., HbA1c, HOMA-IR, hsCRP, vWF). Sample size (n=160; 80\u002Farm) is powered to detect an absolute 20% reduction in CKD progression (35% to 15%) with 80% power and 5% alpha (10% dropout), with intention-to-treat analyses including Kaplan-Meier and Cox regression methods.",[487,26],"MASLD","2026-05-09",{"date":490,"type":38},"2026-05-13",{"date":492,"type":20},"2026-04-15",{"date":494,"type":20},"2028-03-31",{"name":496,"class":45},"Institute of Liver and Biliary Sciences, India",{"id":498,"slug":4,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":16,"minAge":393,"maxAge":262,"enrollmentInfo":504,"targetDuration":4,"studyType":21,"phases":506,"briefSummary":507,"conditions":508,"keywords":515,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":46},"100438049","NCT04984226","Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD","Randomized Cross-over Trial of Sodium Bicarbonate on Muscle Mitochondrial Energetics and Physical Endurance in Chronic Kidney Disease and Metabolic Acidosis","Senergy-CKD","Inclusion Criteria:\n\n* Moderate-severe CKD determined by eGFR \\\u003C50ml\u002Fmin per 1.73m2 by CKD EPI equation on at least 2 consecutive occasions.\n* Metabolic acidosis defined as bicarbonate level\\\u003C24 on two consecutive occasions. Bicarbonate level of 24 or less allowed if eGFR\\\u003C=45ml\u002Fmin per 1.73m2\n* Age 21 to 85 years old\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Poorly controlled diabetes (HgbA1c\\>10%)\n* History of persistent hyperkalemia (K\\>5.4)\n* History of persistent hypokalemia (K\\\u003C3.3)\n* Uncontrolled blood pressure (\\>170\u002F100)\n* Chronic treatment with renal replacement therapy\n* History of aortic dissection or severe valvular heart disease\n* Exercise induced angina\n* Uncontrolled cardiac dysrhythmia\n* Oxygen dependent chronic obstructive pulmonary disease (COPD)\n* Symptomatic claudication\n* End stage liver disease\n* Mobility disability defined as inability to walk without human assistance\n* Dementia or psychosis\n* Patients who cannot consent\n* Active use of intraveneous drugs\n* Non-english speaking\n* History of transplant\n* Implants that prohibit MRI measurements or trauma involving metal fragments\n* Pacemaker\n* Expectation to start dialysis during the course of study.\n* Women who are breastfeeding, pregnant, or are wanting to become pregnant\n* Any condition which in the judgement of the clinical investigator places the participant at risk from participation in the study.\n\nExclusion criteria for optional muscle biopsy\n\n* Drugs- anticoagulants or antiplatelets:\n\n  * Anticoagulants, any 1 (coumadin, rivaroxaban, apixaban, dabigatran, edoxaban)\n  * Antiplatelets, any 2 (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticragrelor, ticlopidine, vorapaxar)\n* Platelet count \\\u003C100,000\n* International normalized ratio (INR)\\>1.4",{"count":505,"type":20},80,[197],"Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.",[26,509,510,511,512,513,514],"Metabolic Acidosis","Fatigue","Physical Endurance","Insulin Resistance","Mitochondrial Energetics","Diabetes",[516,517,518],"Metabolic acidosis","Chronic kidney disease","Insulin resistance","2026-05-04",{"date":521,"type":38},"2026-05-06",{"date":523,"type":38},"2023-09-08",{"date":525,"type":20},"2026-12-31",{"name":527,"class":45},"University of California, Davis",{"id":529,"slug":4,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":413,"enrollmentInfo":534,"targetDuration":4,"studyType":21,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":129},"100559182","NCT06560801","Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation","Randomized Clinical Study to Analyse the Effects of Dapagliflozin on Renal Morphology and Renal Perfusion in Patients With Impaired Renal Function One Year After Kidney Transplantation","Inclusion Criteria:\n\n* Female and male patients aged between 18 and 75 years\n* Patients with renal transplant having a stable eGFR, who are in stable condition, 9 months after transplantation, irrespective of their diabetes status\n* Females of child bearing potential must be using adequate contraceptive precautions\n* Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit\n* Informed consent (§ 40 Abs. 1 Satz 3 Punkt 3 AMG) has to be given in written form\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus.\n* HbA1c \\> 10%\n* Use of SGLT-2 inhibitor within the past 2 months\n* Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 3 months prior to study inclusion.\n* eGFR \\\u003C25 ml\u002Fmin\u002F1.73m² (CKD-EPI Formula).\n* Uncontrolled arterial hypertension (RR \\> 180\u002F110 mmHg).\n* Congestive heart failure (CHF) NYHA stage IV.\n* Recurrent urinary tract infections (bacterial or fungal)\n* Severe disorders of the gastrointestinal tract or other diseases which interfere the pharmacodynamics and pharmacokinetics of the drug.\n* Significant laboratory abnormalities such as SGOT or SGPT levels more than 5 x above the upper limit of normal range.\n* Antihypertensives are allowed but should be kept stable throughout the study period.\n* Statins and other antihyperlipidemic drugs are allowed but should be kept stable throughout the study period.\n* Drug or alcohol abusus\n* Pregnant or breast-feeding patients\n* Patients with contraindications to MRI",{"count":535,"type":20},48,[139],"The aim of this study is to observe the mechanisms of dapagliflozin on the renal interstitial tissue and renal perfusion. For this purpose, renal transplanted patients as an excellent model of CKD and high cardiovascular risk (similar to patients in DAPA-CKD study) are included in this study.\n\nThe objectives of the study are to analyze the effects of dapagliflozin on renal morphology and renal perfusion in patients with impaired renal function one year after kidney transplantation. This is a randomized (1:1), single centre clinical study. Each patient will be randomly assigned in an unblinded fashion to 10 mg Dapagliflozin or not 9 months after transplantation. At least 48 patients will be randomized and included. The routine renal biopsy taken one year after kidney transplantation will allow us to determine the morphological integrity of peritubular fibroblasts, interstitial inflammatory cell density and investigate markers of inflammation, oxidative stress and nitic oxide synthase expression (iNOS).",[26],"2026-04-29",{"date":521,"type":38},{"date":542,"type":38},"2023-07-28",{"date":525,"type":20},{"name":545,"class":45},"University of Erlangen-Nürnberg Medical School",{"id":547,"slug":4,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":11,"sex":16,"minAge":413,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":21,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":566},"100547605","NCT06410144","Chronic Kidney Disease-Education (CKD-EDU)","Improving Kidney Therapy Decision-Making for Older People With Advanced Chronic Kidney Disease (CKD)","CKD-EDU","Inclusion Criteria:\n\n* Age ≥ 75 years old\n* Has advanced kidney disease with kidney function less than 30%\n* Speaks English\n* Has not yet made a dialysis decision\n\nExclusion Criteria:\n\n* Has already decided on dialysis or active medical care without dialysis.\n* Has already been seen by a Palliative Care (PC) clinician for kidney-related issues or is enrolled in hospice\n* Currently on dialysis\n* Unable to provide informed consent or complete verbally administered surveys due to health, sensory, or cognitive impairment.",{"count":554,"type":20},326,[23],"The investigators are conducting a study to see which program better helps older patients with kidney disease choose their treatment. Investigators are also investigating if either program can reduce the number of hospital or emergency room visits in the first 6 months of the study, as well as potentially improve end-of-life care for older adults.\n\nHalf of the participants will receive Program A, while the other half will receive Program B. Investigators will compare the two groups to see which participants feel better prepared about their kidney therapy decisions, experience improved end-of-life care, and have fewer emergency room visits and hospital admissions.\n\nParticipants in Program A will receive information from the National Kidney Foundation and meet with a kidney therapy educator. Participants in Program B will get information about kidney disease treatment and meet with a decision-support specialist who's an expert in decision-making.",[26],{"date":559,"type":38},"2026-05-05",{"date":561,"type":38},"2025-02-27",{"date":563,"type":20},"2028-12-31",{"name":565,"class":45},"University of Rochester",5,{"id":568,"slug":4,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":413,"enrollmentInfo":574,"targetDuration":4,"studyType":21,"phases":576,"briefSummary":577,"conditions":578,"keywords":579,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":46},"100578386","NCT06810622","NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities","Navigate Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities Among Individuals With Kidney Disease","NAV-Kidney","Inclusion Criteria:\n\n* Adults ≥ 18 years of age,\n* Adults who are not pregnant,\n* Adults who are not incarcerated,\n* Adults who have advanced kidney disease with an eGFR of 15-29 mL\u002Fmin\u002F1.73m2). No other measures are used to identify eligible patients.\n\nExclusion Criteria:\n\n* Previous kidney transplant\n* Previous surgery for dialysis such as an arteriovenous fistula, arteriovenous graft, or peritoneal dialysis catheter placement\n* On chronic dialysis\n* Conservative management or primary goal is palliation\n* Incarcerated\n* Pregnant\\*\n* Under 18 years of age\n* Moderate to severe dementia\n* Deaf persons\n* Lacking health insurance\\*\\*\n* Investigator Discretion: Individuals who, in the judgment of the Site PI (or designee), are deemed unsuitable for participation due to behavioral or logistical circumstances that could compromise study integrity or the safety of the participant or staff.",{"count":575,"type":20},448,[197],"The overarching goal of this project is to refine and adapt previous work on the NAVIGATE-Kidney project for individuals with CKD. The investigators hypothesize that the multilevel NAVIGATE-Kidney program intervention will reduce the rate of central venous catheter use at KRT start (primary outcome), increase the rate of optimal KRT starts (secondary outcome), increase patient activation, and reduce decisional conflict (patient-centered outcomes) for individuals with advanced CKD. The project will have four (4) aims.",[91,26],[580,581,582,583],"Kidney","Chronic","Dialysis","Transplant","2026-04-27",{"date":586,"type":38},"2026-05-01",{"date":588,"type":38},"2026-03-18",{"date":590,"type":20},"2029-05-15",{"name":592,"class":45},"University of Colorado, Denver",{"id":594,"slug":4,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":600,"conditions":601,"keywords":604,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":129},"100492457","NCT05692388","Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n1. self- report as AA\u002FBlack\n2. age ≥18\n3. screen positive for 1 or more adversities using the Centers for Medicare and Medicaid Services Accountable Health Communities Health-Related Social Needs Screening tool\n4. self-reported type 2 diabetes and self-report or screen positive for chronic kidney disease (CKD)\n5. able to communicate in English.\n\nExclusion Criteria:\n\n1. cognitive impairment at screening visit\n2. active psychosis\n3. active alcohol or drug abuse\u002Fdependency",{"count":599,"type":20},330,"The overarching goal of this study is to understand facilitators and barriers to self-care, develop and refine a culturally tailored intervention to improve clinical outcomes, quality of life (QOL), and self-care behaviors in African American adults with diabetic kidney disease (DKD) experiencing health-related social needs (HRSN).",[602,603,26],"Diabetic Nephropathy Type 2 - Uncontrolled","Diabetes Mellitus, Type 2",[605],"Social risk factors",{"date":586,"type":38},{"date":608,"type":38},"2023-01-23",{"date":610,"type":20},"2027-03-31",{"name":612,"class":45},"Medical College of Wisconsin",{"id":614,"slug":4,"hasResults":11,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":620,"enrollmentInfo":621,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":623,"conditions":624,"keywords":633,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":647,"locationsCount":129},"100506981","NCT05881447","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in a Primary Care Setting in Semirural Sub-Saharan Africa","RenalTWO","Inclusion Criteria:\n\nall adult patients (≥18 years) attending the outpatients department of the Bagamoyo district hospital (BDH) or the associated Fukayosi and Yombo dispensary\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* not living in the BDH catchment area\n* not of African decent\n* not willing to come back for follow-up visits","99 Years",{"count":622,"type":20},1200,"Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA). Key shortcomings of available data on CKD in SSA are as follows: (i) Available data are based on single measurements and, therefore, cannot distinguish between harmless transient deterioration in kidney function and chronic kidney damage; (ii) Accurate information regarding renal protein loss, an important and early marker of kidney disease, is lacking; (iii) Cardiovascular risk factors for CKD, such as obesity, hypertension and diabetes, are often not searched for. Likewise non-classic potential risk factors, such as endemic infectious diseases, socioeconomic status and lifestyle have not been consistently recorded; (iv) Information to interrogate linked interaction over time between risk factors and development of CKD is unavailable. With this project, situated in a region representative of semi-rural SSA, we aim to fill this knowledge gap and (i) establish guideline conform prevalence data of CKD and its major cardiovascular risk factors, as well as (ii) prospectively define the incidence of cardiovascular- and non-classic risk factors of CKD. The data from (i) and (ii) is used to develop predictive models. A prospective cohort of 1200 individuals in a primary care facility will serve as study population. The population is representing a society in transition from rural to more urban lifestyle. In the pilot study, participants will be followed for one years and undergo the clinical and biomedical testing required to capture CKD and its classic and non-classic risk factors over time.",[26,625,626,627,61,628,629,630,631,142,632],"Type 2 Diabetes Mellitus","Arterial Hypertension","Obesity","HIV Infections","Anemia","Underweight","Infections","Dyslipidemias",[634,635,636,629,637,638,639,640,641],"CKD","Risk factors","Cardiovascular disease","Point of care diagnostics","Albumin creatinine ration (ACR)","Estimated glomerular filtration rate (eGFR)","Kidney Disease: Improving Global Outcomes (KDIGO)","HbA1c","2026-04-23",{"date":539,"type":38},{"date":645,"type":38},"2023-06-21",{"date":525,"type":20},{"name":648,"class":45},"Swiss Tropical & Public Health Institute",""]